Modality
Vaccine
MOA
BETi
Target
SHP2
Pathway
NF-κB
Pancreatic CaGIST
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ Feb 2030
Phase 3Current
NCT05817364
2,937 pts·GIST
2017-08→2030-02·Recruiting
2,937 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-043.8y awayPh3 Readout· GIST
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Recruit…
Catalysts
Ph3 Readout
2030-02-04 · 3.8y away
GIST
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05817364 | Phase 3 | GIST | Recruiting | 2937 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |